Wellgistics Health (NASDAQ:WGRX – Get Free Report) and Summit Therapeutics (NASDAQ:SMMT – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.
Analyst Ratings
This is a summary of current ratings and price targets for Wellgistics Health and Summit Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Wellgistics Health | 1 | 0 | 0 | 0 | 1.00 |
| Summit Therapeutics | 3 | 3 | 9 | 1 | 2.50 |
Summit Therapeutics has a consensus price target of $32.25, indicating a potential upside of 100.06%. Given Summit Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Wellgistics Health.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Wellgistics Health | $34.08 million | 0.64 | -$6.86 million | ($1.17) | -0.21 |
| Summit Therapeutics | N/A | N/A | -$221.32 million | ($1.24) | -13.00 |
Wellgistics Health has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Wellgistics Health, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Wellgistics Health and Summit Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Wellgistics Health | -228.17% | -1,617.25% | -137.41% |
| Summit Therapeutics | N/A | -406.87% | -334.04% |
Insider & Institutional Ownership
4.6% of Summit Therapeutics shares are owned by institutional investors. 44.3% of Wellgistics Health shares are owned by insiders. Comparatively, 84.9% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Summit Therapeutics beats Wellgistics Health on 8 of the 13 factors compared between the two stocks.
About Wellgistics Health
Founded in 2022, Wellgistics Health is a holding company for various existing and planned strategic businesses centered around pharmaceuticals and healthcare services. As a micro health ecosystem, our portfolio of companies consists of a pharmacy, wholesale operations, and a technology division with a novel platform for hub and clinical services. We are focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. In January 2023 and May 2023, Wellgistics Health entered into separate definitive agreements with the owners of Wood Sage and Wellgistics LLC, respectively, whereby Wellgistics Health would acquire all of the respective outstanding membership interests of Wood Sage and Wellgistics LLC. In June 2024, Wellgistics Health and Wood Sage entered into an amended and revised definitive agreement and closed on the Wood Sage Acquisition, thereby making Wood Sage a wholly owned subsidiary of Wellgistics Health. In connection with the Wood Sage Acquisition, Wellgistics Health acquired Wood Sage’s two operating subsidiaries, APS—a pharmaceutical technology hub—and CSP—a retail community specialty pharmacy. On August 30, 2024, Wellgistics Health closed on the Wellgistics Acquisition, thereby making Wellgistics LLC—a company focused on wholesale operations including the distribution and fulfillment of certain pharmaceutical medications to a network of independent pharmacies meant to improve market access to and patient outcomes regarding the medications—a wholly owned subsidiary of Wellgistics Health. As such, Wellgistics Health currently exists as a holding company with Wood Sage as a directly held intermediate holding company subsidiary, APS and CSP as indirect operating subsidiaries, and Wellgistics LLC as a direct operating subsidiary. On October 4, 2024, the Company changed its corporate name to “Wellgistics Health, Inc.” by filing a duly authorized Certificate of Amendment to its Certificate of Incorporation. Despite that Wellgistics Health only recently closed the Wood Sage Acquisition and the Wellgistics Acquisition during 2024, the three companies have shared common office space, comarketed solutions to the marketplace, and leveraged financial and back-office support prior to June 2024. As such, Wellgistics Health’s management believes that its close business relationships have and will continue to limit the need for post-closing integration. The mailing address of our principal executive office is 3000 Bayport Drive, Suite 950 Tampa, FL.
About Summit Therapeutics
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
Receive News & Ratings for Wellgistics Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wellgistics Health and related companies with MarketBeat.com's FREE daily email newsletter.
